Nkarta, Inc. Profile Avatar - Palmy Investing

Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cel…

Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Nkarta, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Nkarta, Inc. can't present revenue by segment

End of NKTX's Analysis
CIK: 1787400 CUSIP: 65487U108 ISIN: US65487U1088 LEI: - UEI: -
Secondary Listings
NKTX has no secondary listings inside our databases.